USFDA completes PADE inspection at Marksans Pharma’s Goa facility

07 Aug 2023 Evaluate

United State Food and Drug Administration (USFDA) has completed Post-marketing Adverse Drug Experience (PADE) inspection at Marksans Pharma’s Goa, Verna manufacturing facility. The inspection closed with two observations. The inspection was conducted from July 31, 2023 to August 04, 2023. The inspection included comprehensive scrutiny of practices and procedures for reporting of adverse events of Marksans' marketed products. 

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.

Marksans Pharma Share Price

183.95 -3.95 (-2.10%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×